This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hess, V. Articles by Gore, M. E. Search for Related Content PubMed PubMed Citation Articles by Hess, V. Articles by Gore, M. E. Social Bookmarking                            What's this?

Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment

From the the Gynaecology Unit, Royal Marsden Hospital, London, United Kingdom.

Address reprint requests to Martin Gore, PhD, FRCP, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, United Kingdom; e-mail: martin.gore{at}rmh.nthames.nhs.uk

PURPOSE: Invasive mucinous carcinoma of the ovary (mucinous epithelial ovarian cancer [mEOC]) is a histologic subgroup of epithelial ovarian cancer (EOC). Chemotherapy for mEOC is chosen according to guidelines established for EOC. The purpose of this study is to determine whether this is appropriate.

PATIENTS AND METHODS: Women with advanced mEOC (International Federation of Gynecology and Obstetrics stage III or IV) who underwent first-line platinum-based chemotherapy were compared with women with other histologic subtypes of EOC in a case-controlled study.

RESULTS: Eighty-one patients (27 cases, 54 controls) treated with platinum-based regimens were analyzed. The response rates for cases and controls were 26.3% (95% CI, 9.2% to 51.2%) and 64.9% (95% CI, 47.5% to 79.8%), respectively (P = .01). The odds ratio for complete or partial response to chemotherapy for mEOC was 0.19 (95% CI, 0.06 to 0.66; P = .009) compared with other histologic subtypes of EOC. Median progression-free survival was 5.7 months (95% CI, 1.9 to 9.6 months) versus 14.1 months (95% CI, 12.0 to 16.2 months; P < .001) and overall survival was 12.0 months (95% CI, 8.0 to 15.6 months) versus 36.7 months (95% CI, 25.2 to 48.2 months; P < .001) for cases and controls, respectively. The hazard ratio for progression and death was 2.94 (95% CI, 1.71 to 5.07; P < .001) and 3.08 (95% CI, 1.69 to 5.6; P < .001), respectively, for mEOC patients as compared with controls.

CONCLUSION: Patients with advanced mEOC have a poorer response to platinum-based first-line chemotherapy compared with patients with other histologic subtypes of EOC, and their survival is worse. Specific alternative therapeutic approaches should be sought for this group of patients, perhaps involving fluorouracil-based chemotherapy.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. E. Winter III, G. L. Maxwell, C. Tian, J. W. Carlson, R. F. Ozols, P. G. Rose, M. Markman, D. K. Armstrong, F. Muggia, and W. P. McGuire Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., August 20, 2007; 25(24): 3621 - 3627. [Abstract] [Full Text] [PDF]

				V. A Heinzelmann-Schwarz, R. A Scolyer, J. P Scurry, A. N Smith, M. Gardiner-Garden, A. V Biankin, S. Baron-Hay, C. Scott, R. L Ward, D. Fink, et al. Low meprin {alpha} expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries J. Clin. Pathol., June 1, 2007; 60(6): 622 - 626. [Abstract] [Full Text] [PDF]

				F. W. Wamunyokoli, T. Bonome, J.-Y. Lee, C. M. Feltmate, W. R. Welch, M. Radonovich, C. Pise-Masison, J. Brady, K. Hao, R. S. Berkowitz, et al. Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance Clin. Cancer Res., February 1, 2006; 12(3): 690 - 700. [Abstract] [Full Text] [PDF]

				F. V. Negri, A. Wotherspoon, D. Cunningham, A. R. Norman, G. Chong, and P. J. Ross Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer Ann. Onc., August 1, 2005; 16(8): 1305 - 1310. [Abstract] [Full Text] [PDF]

				K. A. Shedden, M. P. Kshirsagar, D. R. Schwartz, R. Wu, H. Yu, D. E. Misek, S. Hanash, H. Katabuchi, L. H. Ellenson, E. R. Fearon, et al. Histologic Type, Organ of Origin, and Wnt Pathway Status: Effect on Gene Expression in Ovarian and Uterine Carcinomas Clin. Cancer Res., March 15, 2005; 11(6): 2123 - 2131. [Abstract] [Full Text] [PDF]